America’s Obesity Rate Is Finally Falling

Editors’ Note: Happy National Muscle Health month!

Or copy and paste this link to others: {{rp_refer_url}}

This time of year, it’s so easy for your daily routine to be thrown off.

When it starts getting dark before you’re home from work and the Halloween candy is taunting you, it’s important to find something that’s easy to do daily for your body.

That’s where AG1 Next Gen comes in.

With just one quick scoop every morning, you’ll get over 75 ingredients that help support your immune health, gut health, energy and help to close nutrient gaps in your diet.

Click here and you’ll get a free AG1 welcome kit with your first subscription including a:

✔️ FREE Flavor Sample Pack
✔️ FREE Bottle Vitamin D3+K2 Drops
✔️ FREE Canister + Shaker

It’s one of the easiest things you can do for your body every day.

Click here

_{*These statements have not been evaluated by the Food and Drug Administration.}

For the first time in more than a decade, the U.S. obesity rate is declining. According to new Gallup data, the percentage of adults with obesity has dropped from 39.9% in 2022 to 37.0% in 2025. That may sound small, but it represents nearly eight million fewer obese adults in just three years.

At the same time, diabetes diagnoses have hit a record high of 13.8%. In other words, Americans are losing weight, but metabolic disease isn’t going away.

What’s driving the drop

The story is what you would expect: the GLP-1 era. Use of injectable weight-loss drugs like Ozempic and Wegovy has more than doubled since early 2024, with 12.4% of U.S. adults now taking them for weight management. Awareness of the drugs has climbed to nearly 90%.

Women are leading adoption (15.2% compared to 9.7% for men), and they’ve seen slightly larger declines in obesity rates. The biggest decreases come from adults aged 40 to 64. It’s the first visible population-level effect of the drugs that have reshaped how the world thinks about weight.

Who’s not seeing results

The youngest adults and seniors haven’t seen much change in obesity rates. Among older adults, the drugs also seem less effective for weight loss.

Even with the national decline, the U.S. remains one of the most obese developed countries. Access and affordability play a major role. Only 13 states currently cover GLP-1s under Medicaid, and cost continues to block wide use for lower-income Americans.

A new relationship with weight

The shift we’re seeing goes deeper than weight alone. GLP-1s are pushing a national conversation about metabolism, appetite, behavior, and muscle.

While these drugs help reduce fat mass, they also tend to reduce lean mass if resistance training and protein intake aren’t prioritized. Losing weight at the expense of muscle can lead to weaker metabolism, reduced strength, and poorer long-term health outcomes.

The key question now isn’t just “Can we lose weight?” but “Can we lose the right kind of weight while keeping muscle?”

Why you should care

Even with millions using GLP-1s, diabetes rates continue to rise. Because diabetes is a lifetime condition, that number doesn’t fall unless new cases slow down. Medication helps, but it can’t replace movement, nutrition, and habits that strengthen muscle and regulate glucose.

The U.S. still reports worse health habits than it did before the pandemic. The drugs may buy time, but lifestyle still determines whether that time translates to better healthspan.

The GLP-1 revolution is redefining obesity care. If America treats GLPs as a medication-only fix, the progress will be temporary. Real metabolic health depends on muscle to burn glucose, stabilize hormones, and keep weight off for the long term.

Or copy and paste this link to others: {{rp_refer_url}}

Current Referral Count: {{rp_num_referrals}}